[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010058926A3 - 생강 추출물 또는 쇼가올을 포함하는 약학 조성물 - Google Patents

생강 추출물 또는 쇼가올을 포함하는 약학 조성물 Download PDF

Info

Publication number
WO2010058926A3
WO2010058926A3 PCT/KR2009/006664 KR2009006664W WO2010058926A3 WO 2010058926 A3 WO2010058926 A3 WO 2010058926A3 KR 2009006664 W KR2009006664 W KR 2009006664W WO 2010058926 A3 WO2010058926 A3 WO 2010058926A3
Authority
WO
WIPO (PCT)
Prior art keywords
shogaol
pharmaceutical composition
ginger extract
composition containing
containing ginger
Prior art date
Application number
PCT/KR2009/006664
Other languages
English (en)
French (fr)
Other versions
WO2010058926A2 (ko
Inventor
김선여
하상근
류종훈
오명숙
정서영
Original Assignee
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080114964A external-priority patent/KR20100056020A/ko
Priority claimed from KR1020080118585A external-priority patent/KR20100060124A/ko
Priority claimed from KR1020080118582A external-priority patent/KR101288814B1/ko
Application filed by 경희대학교 산학협력단 filed Critical 경희대학교 산학협력단
Priority to US13/130,009 priority Critical patent/US9844521B2/en
Priority to CN200980146308.4A priority patent/CN102215857B/zh
Publication of WO2010058926A2 publication Critical patent/WO2010058926A2/ko
Publication of WO2010058926A3 publication Critical patent/WO2010058926A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 생강 추출물 또는 쇼가올; 및 약학적으로 허용가능한 담체를 포함하는, 학습 장애, 기억력 장애, 파킨슨 질환, 또는 허혈성 뇌혈관 질환의 예방 또는 치료용 약학 조성물을 제공한다. 또한, 본 발명은 생강 추출물 또는 쇼가올을 유효성분으로 포함하는, 학습 장애 또는 기억력 장애의 개선 또는 증상완화용 식품 조성물 또는 학습 또는 기억력 증진용 식품 조성물을 제공한다.
PCT/KR2009/006664 2008-11-19 2009-11-13 생강 추출물 또는 쇼가올을 포함하는 약학 조성물 WO2010058926A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/130,009 US9844521B2 (en) 2008-11-19 2009-11-13 Pharmaceutical composition comprising ginger extract or shogaol
CN200980146308.4A CN102215857B (zh) 2008-11-19 2009-11-13 包含生姜提取物或姜烯酚的药物组合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR1020080114964A KR20100056020A (ko) 2008-11-19 2008-11-19 생강 추출물 또는 쇼가올을 포함하는 학습 또는 기억력 증진용 조성물
KR10-2008-0114964 2008-11-19
KR1020080118585A KR20100060124A (ko) 2008-11-27 2008-11-27 생강 추출물 또는 쇼가올을 포함하는 허혈성 뇌혈관 질환의 예방 또는 치료용 약학 조성물
KR1020080118582A KR101288814B1 (ko) 2008-11-27 2008-11-27 생강 추출물 또는 쇼가올을 포함하는 파킨슨 질환의 예방 또는 치료용 약학 조성물
KR10-2008-0118585 2008-11-27
KR10-2008-0118582 2008-11-27

Publications (2)

Publication Number Publication Date
WO2010058926A2 WO2010058926A2 (ko) 2010-05-27
WO2010058926A3 true WO2010058926A3 (ko) 2010-09-23

Family

ID=42198634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006664 WO2010058926A2 (ko) 2008-11-19 2009-11-13 생강 추출물 또는 쇼가올을 포함하는 약학 조성물

Country Status (3)

Country Link
US (1) US9844521B2 (ko)
CN (1) CN102215857B (ko)
WO (1) WO2010058926A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
CN102657841A (zh) * 2012-06-08 2012-09-12 桂林三金药业股份有限公司 一种生姜酚类提取物制剂及其制备方法
US11229600B2 (en) * 2014-09-24 2022-01-25 Vital Beverages Global Inc. Compositions and methods for selective GI tract delivery
CN109414468B (zh) * 2016-04-27 2021-09-10 弗拉基米尔·巴德玛耶夫 利用姜烯酚维持体内铁质平衡的方法
CN106187727A (zh) * 2016-07-27 2016-12-07 陕西嘉禾生物科技股份有限公司 一种从天堂椒果实中提取6‑姜酮酚的方法
WO2018129315A1 (en) * 2017-01-06 2018-07-12 Flex Pharma, Inc. Methods and compositions for the treatment of disease
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
CN107583027A (zh) * 2017-11-01 2018-01-16 周杰 疏经通络的中药制剂、制备方法及其应用
KR102176033B1 (ko) * 2020-05-28 2020-11-06 주식회사 하나모아 생강 추출물을 함유하는 생강수 조성물 및 그 제조 방법
WO2024101890A1 (ko) * 2022-11-09 2024-05-16 경희대학교 산학협력단 건강 추출물, 쇼가올 및 레보도파를 유효성분으로 포함하는 파킨슨병 또는 도파민 유발 이상운동증의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095424A1 (fr) * 2002-05-13 2003-11-20 Toagosei Co., Ltd. Procede de production de shogaol et produits intermediaires servant a la synthese de shogaol
KR20080041625A (ko) * 2005-06-15 2008-05-13 대릭 에스. 에치. 엘. 김 세이지 및 로즈마리 유도 화합물을 포함하는,베타-아밀로이드 단백질 유발 질환의 예방 및 치료에유용한 상승 작용성 약학 조성물
US20080193574A1 (en) * 2006-09-29 2008-08-14 Rishton Gilbert M Inhibitors Of Cognitive Decline

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263909A (ja) * 1985-05-20 1986-11-21 Shiseido Co Ltd 皮膚外用剤
JPS6372625A (ja) 1986-09-12 1988-04-02 Tsumura & Co 血小板凝集抑制剤
JPH02193930A (ja) * 1989-01-19 1990-07-31 Tsumura & Co ラジカル消去剤
US6518315B1 (en) * 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
US7728043B2 (en) 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
US6887898B1 (en) 1999-10-22 2005-05-03 Darrick S. H. L. Kim Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease
DE10320560A1 (de) * 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods
US7455860B2 (en) * 2004-08-11 2008-11-25 Laila Nutraceuticals Dietary supplement formulation for controlling inflammation and cancer
CN1692924A (zh) * 2005-02-25 2005-11-09 广州中医药大学 姜提取物及其制备方法和应用
US8017162B2 (en) * 2005-10-26 2011-09-13 Oryza Oil & Fat Chemical Co., Ltd. Anti-inflammatory agent
JP2008156297A (ja) * 2006-12-25 2008-07-10 Hokkaido Univ セロトニン２ｂおよび／または２ｃ受容体拮抗剤
WO2009143065A2 (en) * 2008-05-18 2009-11-26 Rice Science, Llc Rice bran extracts and methods of use thereof
AU2009263735B2 (en) * 2008-06-03 2014-10-02 Laila Nutraceuticals Compositions comprising extracts from Boswellia serrata

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095424A1 (fr) * 2002-05-13 2003-11-20 Toagosei Co., Ltd. Procede de production de shogaol et produits intermediaires servant a la synthese de shogaol
KR20080041625A (ko) * 2005-06-15 2008-05-13 대릭 에스. 에치. 엘. 김 세이지 및 로즈마리 유도 화합물을 포함하는,베타-아밀로이드 단백질 유발 질환의 예방 및 치료에유용한 상승 작용성 약학 조성물
US20080193574A1 (en) * 2006-09-29 2008-08-14 Rishton Gilbert M Inhibitors Of Cognitive Decline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DARRICK S.H.L.KIM ET AL.: "Side-chain length is important for shogaols in protecting neuronal cells from beta-amyloid insult", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 1287 - 1289 *

Also Published As

Publication number Publication date
CN102215857A (zh) 2011-10-12
WO2010058926A2 (ko) 2010-05-27
US9844521B2 (en) 2017-12-19
US20110229590A1 (en) 2011-09-22
CN102215857B (zh) 2015-06-17

Similar Documents

Publication Publication Date Title
WO2010058926A3 (ko) 생강 추출물 또는 쇼가올을 포함하는 약학 조성물
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006128692A3 (en) 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
MX2010002780A (es) Formulacion de farmaco resistente al abuso.
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
IL189008A (en) History of 1-Naphthalenyl-3-azabicyclo [0.1.3] hexane
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2008070268A3 (en) Pharmaceutical compositions
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
PL2083809T3 (pl) Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
WO2007144169A3 (en) Entacapone-derivatives
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2009118726A3 (en) Oral combination of vitamins
WO2012017435A3 (en) Soybean extracts for the treatment of hepatic disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146308.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827691

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13130009

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09827691

Country of ref document: EP

Kind code of ref document: A2